1-9 of 9
Ignacio Gil-Bazo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT162: Trial in progress: A phase I, open-label, multicenter study of ZL-1218, an anti-CCR8 IgG1, as a single agent and as combination therapy with anti-PD-1 antibody to evaluate the safety, tolerability, and pharmacokinetics in subjects with advanced solid tumor

Elena Garralda, Valentina Boni, David Vincente Baz, Arvind Chaudhry, Ignacio Gil Bazo, Martin Gutierrez, Jyoti Malhotra, Casal Guzman Alonso, Valentina Gambardella, Michael Chisamore, Renke Zhou, Maria Tea, Deborah Doroshow
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT162.
https://doi.org/10.1158/1538-7445.AM2024-CT162
Published: 05 April 2024
View article titled, Abstract CT162: Trial in progress: A phase I, open-label, multicenter study of ZL-1218, an anti-CCR8 IgG1, as a single agent and as combination therapy with anti-PD-1 antibody to evaluate the safety, tolerability, and pharmacokinetics in subjects with advanced solid tumor
Journal Articles

Abstract 5712: Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade

Namrata S. Patil, Shyam Srivats, Yoonha Choi, Xiangnan Guan, Barzin Nabet, Lisa McGinnis, Eugene Chiang, Alexis Dunkle, Bill O’Gorman, Patrick S. Chang, Ruozhen Hu, John Silva, Joy Han, Amelia Au-Yeung, Chikara Takahashi, Nandini Molden, Pallavi Daggumati, Wendy Connolly, Melissa Johnson, Delvys Rodriguez Abreu, Byoung Chul Cho, Antoine Italiano, Ignacio Gil-Bazo, Enriqueta Felip, Ira Mellman, Raymond Meng, Sanjeev Mariathasan, Robert Johnston, David S. Shames
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5712.
https://doi.org/10.1158/1538-7445.AM2023-5712
Published: 04 April 2023
View article titled, Abstract 5712: Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade
Journal Articles

Abstract CT197: Phase Ib study of LXH254 + trametinib (TMT) in patients (pts) with NRAS-mutant melanoma

Filippo de Braud, Christophe Dooms, Rebecca S. Heist, Celeste Lebbe, Martin Wermke, David Planchard, Dirk Schadendorf, Piotr Rutkowski, Jürgen Wolf, Paolo A. Ascierto, Ignacio Gil-Bazo, Shumei Kato, Maria Wolodarski, Meredith McKean, Eva Muñoz Couselo, Martin Sebastian, Armando Santoro, Vesselina Cooke, Luca Manganelli, Kitty Wan, Anil Gaur, Tanay S. Samant, Jaeyeon Kim, Giordano Caponigro, Xuân-Mai Couillebault, Michele Moschetta, Adil Daud
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT197.
https://doi.org/10.1158/1538-7445.AM2022-CT197
Published: 15 June 2022
View article titled, Abstract CT197: Phase Ib study of LXH254 + trametinib (TMT) in patients (pts) with <em>NRAS</em>-mutant melanoma
Journal Articles

Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network

Marta Román, Inés López, Elisabeth Guruceaga, Iosune Baraibar, Margarita Ecay, María Collantes, Ernest Nadal, Adrián Vallejo, Silvia Cadenas, Marta Echavarri-de Miguel, Jae Hwi Jang, Patxi San Martin-Uriz, Laura Castro-Labrador, Amaia Vilas-Zornoza, David Lara-Astiaso, Mariano Ponz-Sarvise, Christian Rolfo, Edgardo S. Santos, Luis E. Raez, Simona Taverna, Carmen Behrens, Walter Weder, Ignacio I. Wistuba, Silvestre Vicent, Ignacio Gil-Bazo
Journal: Cancer Research
Cancer Res (2019) 79 (3): 625–638.
https://doi.org/10.1158/0008-5472.CAN-18-1479
Published: 01 February 2019
View article titled, Inhibitor of Differentiation-1 Sustains Mutant <em>KRAS</em>-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network
Open the PDF for Inhibitor of Differentiation-1 Sustains Mutant <em>KRAS</em>-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network in another window
Includes: Supplementary data
Journal Articles

Abstract CT017: Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

Maria E. Rodriguez-Ruiz, Jose L. Perez-Gracia, Inmaculada Rodriguez, Carlos Alfaro, Ignacio Gil-Bazo, Alfonso Gurpide, Andres Salazar, Ignacio Melero
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT017.
https://doi.org/10.1158/1538-7445.AM2018-CT017
Published: 01 July 2018
View article titled, Abstract CT017: Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
Journal Articles

Abstract 1996: Inhibitor of differentiation-1 (Id1) expression deficiency in the tumor microenvironment impairs experimental hepatic metastasis of lung cancer

Ignacio Gil-Bazo, Eduardo Castanon, Inés López, Victor Segura, Mariano Ponz-Sarvise, José M. López-Picazo, Maria Collantes, Margarita Ecay, Isabel Gil-Aldea, Alfonso Calvo, Fernando Vidal-Vanaclocha
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 1996.
https://doi.org/10.1158/1538-7445.AM2014-1996
Published: 01 October 2014
View article titled, Abstract 1996: Inhibitor of differentiation-1 (Id1) expression deficiency in the tumor microenvironment impairs experimental hepatic metastasis of lung cancer
Journal Articles

Abstract 2219: Inhibitor of differentiation-1 is a novel prognostic factor among NSCLC patients with adenocarcinoma histology and contributes to therapy resistance

Mariano Ponz-Sarvise, Paul A. Nguewa, Maria J. Pajares, Jackeline Agorreta, Maria D. Lozano, Miriam Redrado, Ruben Pio, Carmen Behrens, Ignacio Wistuba, Jesus Garcia-Foncillas, Luis M. Montuenga, Alfonso Calvo, Ignacio Gil-Bazo
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 2219.
https://doi.org/10.1158/1538-7445.AM2011-2219
Published: 15 April 2011
View article titled, Abstract 2219: Inhibitor of differentiation-1 is a novel prognostic factor among NSCLC patients with adenocarcinoma histology and contributes to therapy resistance
Journal Articles

Abstract #3734: Inhibition of non-small cell lung cancer growth by the tyrosine-kinase inhibitors sunitinib and lapatinib through targeting both tumor and tumor-accessory cells

Raul Catena, Paul Nguewa, Roque Díaz, Ignacio Gil-Bazo, Miriam Redrado, Alfonso Calvo
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 3734.
Published: 01 May 2009
View article titled, Abstract #3734: Inhibition of non-small cell lung cancer growth by the tyrosine-kinase inhibitors sunitinib and lapatinib through targeting both tumor and tumor-accessory cells
Journal Articles

Reassessment of Id1 Protein Expression in Human Mammary, Prostate, and Bladder Cancers Using a Monospecific Rabbit Monoclonal Anti-Id1 Antibody

Jonathan Perk, Ignacio Gil-Bazo, Yvette Chin, Paola de Candia, John J.S. Chen, Yuntao Zhao, Shirley Chao, Wai Cheong, Yaohuang Ke, Hikmat Al-Ahmadie, William L. Gerald, Edi Brogi, Robert Benezra
Journal: Cancer Research
Cancer Res (2006) 66 (22): 10870–10877.
https://doi.org/10.1158/0008-5472.CAN-06-2643
Published: 15 November 2006
View article titled, Reassessment of Id1 Protein Expression in Human Mammary, Prostate, and Bladder Cancers Using a Monospecific Rabbit Monoclonal Anti-Id1 Antibody
Open the PDF for Reassessment of Id1 Protein Expression in Human Mammary, Prostate, and Bladder Cancers Using a Monospecific Rabbit Monoclonal Anti-Id1 Antibody in another window